KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Gsk (GSK) EBT (2016 - 2026)

Gsk has reported EBT over the past 18 years, most recently at $2.9 billion for Q1 2026.

  • For Q1 2026, EBT rose 8.87% year-over-year to $2.9 billion; the TTM value through Mar 2026 reached $10.0 billion, up 20.55%, while the annual FY2025 figure was $9.8 billion, 120.59% up from the prior year.
  • EBT for Q1 2026 was $2.9 billion at Gsk, up from $1.3 billion in the prior quarter.
  • Over five years, EBT peaked at $4.8 billion in Q4 2023 and troughed at $83.2 million in Q3 2024.
  • A 5-year average of $2.4 billion and a median of $2.5 billion in 2023 define the central range for EBT.
  • Biggest five-year swings in EBT: crashed 96.33% in 2024 and later soared 3885.36% in 2025.
  • Year by year, EBT stood at $3.5 billion in 2022, then skyrocketed by 37.81% to $4.8 billion in 2023, then fell by 24.31% to $3.7 billion in 2024, then plummeted by 65.45% to $1.3 billion in 2025, then surged by 128.74% to $2.9 billion in 2026.
  • Business Quant data shows EBT for GSK at $2.9 billion in Q1 2026, $1.3 billion in Q4 2025, and $3.3 billion in Q3 2025.